DrugPatentWatch Database Preview
Bristol Myers Squibb Company Profile
What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?
There are seventeen US patents protecting BRISTOL MYERS SQUIBB drugs.
There are four hundred and forty-seven patent family members on BRISTOL MYERS SQUIBB drugs in fifty-seven countries and one hundred and seventy-six supplementary protection certificates in fifteen countries.
Summary for Bristol Myers Squibb
International Patents: | 447 |
US Patents: | 17 |
Tradenames: | 66 |
Ingredients: | 58 |
NDAs: | 77 |
Drugs and US Patents for Bristol Myers Squibb
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-002 | Jun 28, 2006 | AB | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Bristol Myers Squibb | AZACTAM IN PLASTIC CONTAINER | aztreonam | INJECTABLE;INJECTION | 050632-001 | May 24, 1989 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-003 | Apr 22, 1996 | DISCN | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
Bristol Myers Squibb | STILBETIN | diethylstilbestrol | TABLET, DELAYED RELEASE;ORAL | 004056-012 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Bristol Myers Squibb
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-006 | Oct 28, 1999 | 4,861,759*PED | ➤ Try a Free Trial |
Bristol Myers Squibb | PRAVIGARD PAC (COPACKAGED) | aspirin; pravastatin sodium | TABLET, TABLET, TABLET;ORAL | 021387-005 | Jun 24, 2003 | 4,346,227*PED | ➤ Try a Free Trial |
Bristol Myers Squibb | VIDEX | didanosine | FOR SOLUTION;ORAL | 020155-005 | Oct 9, 1991 | 4,861,759*PED | ➤ Try a Free Trial |
Bristol Myers Squibb | SUSTIVA | efavirenz | CAPSULE;ORAL | 020972-003 | Sep 17, 1998 | 5,519,021*PED | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
Non-Orange Book US Patents for Bristol Myers Squibb
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,382,219 | Cyclic protein tyrosine kinase inhibitors | ➤ Try a Free Trial |
8,716,323 | Cyclic protein tyrosine kinase inhibitors | ➤ Try a Free Trial |
6,858,616 | Nitrogen containing heterobicycles as factor Xa inhibitors | ➤ Try a Free Trial |
7,338,963 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents for Bristol Myers Squibb Drugs
Country | Document Number | Estimated Expiration |
---|---|---|
Argentina | 047533 | ➤ Try a Free Trial |
Slovenia | 1427415 | ➤ Try a Free Trial |
China | 1989969 | ➤ Try a Free Trial |
China | 101357914 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Bristol Myers Squibb Drugs
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
01C/001 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: EFAVIRENZ; NATL. REGISTRATION NO/DATE: EU/1/99/110/001 19990604; FIRST REGISTRATION: CH 54908 01 19981120 |
13/34 | Ireland | ➤ Try a Free Trial | PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013 |
/2012 | Austria | ➤ Try a Free Trial | PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124 |
2016039 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: ATAZANAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/15/1025 20150713 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.